## Benefits of tiotropium/olodaterol in patients with COPD receiving only LAMA at baseline: pooled analysis of TONADO®/OTEMTO®

## TONADO® 1+2

Phase III, randomised, double-blind trials in patients with moderate-to-very severe COPD (52 weeks)

## **OTEMTO® 1+2**

Phase III, randomised, double-blind trials in patients with moderate-to-severe COPD (12 weeks)

Post hoc analysis of


299



patients from TONADO® and OTEMTO®
who were receiving only
LAMA at study entry

Patients received T/O 5/5 µg or tio 5 µg





<sup>a</sup>Mean difference between T/O 5/5 μg and tio 5 μg after 12 weeks in patients receiving LAMA at baseline Similar adverse event profiles were noted between the two treatment arms

Conclusion: these results support treatment escalation to dual bronchodilation in patients receiving LAMA monotherapy, without compromising patient safety

COPD, chronic obstructive pulmonary disease; FEV<sub>1</sub>, forced expiratory volume in 1 second; LAMA, long-acting muscarinic antagonist; SGRQ, St. George's Respiratory Questionnaire; T/O, tiotropium/olodaterol; TDI, Transition Dyspnoea Index; tio, tiotropium





